ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

• Main Authors: Krishnarup Ghoshdastidar (Author), Hoshang Patel (Author), Hitesh Bhayani (Author), Ankit Patel (Author), Kinjal Thakkar (Author), Dinesh Patel (Author), Manoranjan Sharma (Author), Jaideep Singh (Author), Jogeswar Mohapatra (Author), Abhijit Chatterjee (Author), Dipam Patel (Author), Rajesh Bahekar (Author), Rajiv Sharma (Author), Lakshmikant Gupta (Author), Nirmal Patel (Author), Poonam Giri (Author), Nuggehally R. Srinivas (Author), Mukul Jain (Author), Debdutta Bandyopadhyay (Author), Pankaj R. Patel (Author), Ranjit C. Desai (Author)
• Format: Book
• Published: Wiley, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhibitor that inhibits the ibrutinib‐resistant C...